Search results for "Dexamethasone"

showing 10 items of 246 documents

Sudden Sensorineural Hearing Loss: Results of intratympanic steroids as salvage treatment

2012

Objective: The aim of the present study was to verify the efficacy and the safety of intratympanic dexamethasone to treat sudden sensorineural hearing loss as salvage therapy. Materials and methods: A prospective study was conducted on patients affected by idiopathic sudden hearing loss who were treated before with some systemic therapy, but without recovery of the hearing The patients able to undergo the study, but who refused salvage treatment were considered as control group. A solution of Dexamethasone 4 mg/ml was then injected through the posterior–inferior quadrant filling completely the middle ear. The follow-up in the following 6 months included an audiogram every month. Results: Th…

AdultMalemedicine.medical_specialtyTympanic MembraneAdolescentNeurosensorial Hearing Loss Steroids treatmentHearing lossHearing Loss SensorineuralSalvage therapyInjections IntralesionalAudiologyRisk AssessmentSystemic therapyDexamethasoneYoung AdultConfidence IntervalsOdds Ratiootorhinolaryngologic diseasesmedicineHumansProspective StudiesProspective cohort studyDexamethasoneAgedSalvage TherapyAnalysis of VarianceAbsolute threshold of hearingmedicine.diagnostic_testbusiness.industryAudiogramHearing Loss SuddenMiddle AgedTreatment OutcomeSettore MED/31 - OtorinolaringoiatriaOtorhinolaryngologyCase-Control StudiesAnesthesiaAudiometry Pure-ToneFemaleAudiometrymedicine.symptombusinessFollow-Up Studiesmedicine.drugAmerican Journal of Otolaryngology
researchProduct

Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study.

2011

The aim of this study was to verify the efficacy and the safety of transtympanic dexamethasone to treat sudden sensorineural hearing loss as first and single drug method. Considering ethical implication of performing a mininvasive procedure on middle ear, we matched such proposed treatment with systemic prednisone administration that represents the widest adopted protocol. Randomized prospective study was conducted. The inclusion criterion was a sudden sensorineural hearing loss of at least 30 dB across three contiguous frequencies over a period of 24 h. Group A received transtympanic steroid injections; Group B received oral administration of steroids. 25 patients were treated with transty…

AdultMalemedicine.medical_specialtyTympanic MembraneHearing Loss SensorineuralAdministration OralInjections IntralesionalRisk AssessmentSeverity of Illness IndexDexamethasoneDrug Administration ScheduleAudiometryOral administrationPrednisoneSeverity of illnessmedicineHumansProspective StudiesProspective cohort studyDexamethasoneAgedAnalysis of Variancemedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryGeneral MedicineHearing Loss SuddenMiddle AgedSurgeryCochlea Deafness Round window Sudden sensorineural hearing loss Steroid TranstympanicTreatment OutcomeOtorhinolaryngologyOtorhinolaryngologyFemaleNeurosurgeryAudiometrybusinessmedicine.drugFollow-Up Studies
researchProduct

Intratympanic Dexamethasone/Hyaluronic Acid Mix as an Adjunct to Intravenous Steroid and Vasoactive Treatment in Patients With Severe Idiopathic Sudd…

2011

To evaluate differences in effectiveness (hearing recovery rates) between idiopathic sudden sensorineural hearing loss (ISSNHL) patients treated with intravenous therapy alone and patients treated with a combination of intravenous and intratympanic therapy.Retrospective case review.Tertiary referral hospital center.Ninety-four patients with moderate ISSNHL treated with an intravenous steroid and vasoactive regimen (duration of therapy, 9 ± 2.76 d) and 76 patients with severe ISSNHL treated with a combination regimen of intravenous and intratympanic therapy (duration of therapy, 10 ± 2.71 d) were reviewed. In the latter patients' group, a series of 3 intratympanic injections of a dexamethaso…

AdultMalemedicine.medical_specialtyTympanic MembraneHearing Loss Sensorineuralmedicine.medical_treatmentIntratympanic dexamethasoneDexamethasoneInjectionsSteroidchemistry.chemical_compoundVasoactiveInternal medicineHyaluronic acidotorhinolaryngologic diseasesmedicineHumansIn patientHyaluronic AcidGlucocorticoidsRetrospective Studiesbusiness.industryHearing Loss SuddenSensory SystemsHearing recoveryTreatment OutcomeEndocrinologyOtorhinolaryngologychemistryIntravenous therapyAnesthesiaSudden sensorineural hearing lossInjections IntravenousAudiometry Pure-ToneFemaleSteroidsNeurology (clinical)businessOtology & Neurotology
researchProduct

Intratympanic Dexamethasone and Hyaluronic Acid in Patients with Low-Frequency and Ménière's-Associated Sudden Sensorineural Hearing Loss

2005

Steroids are widely used for the treatment of cochleovestibular disorders. Direct steroid application in the middle ear cavity, when combined with a round window membrane permeability-modulating substance, increases the level of the steroid reaching the target cells. We measured hearing in patients with idiopathic isolated low-frequency sensorineural hearing loss and in patients with sudden sensorineural hearing loss and a history of Ménière's disease. Contradictory reports about effectiveness of intratympanic steroid therapy on vertigo control and hearing improvement in patients with Ménière's disease exist in the literature.Eighteen patients with isolated low-frequency idiopathic sudden s…

AdultMalemedicine.medical_specialtyTympanic MembraneHearing lossHearing Loss SensorineuralAnti-Inflammatory AgentsInjections IntralesionalAudiologyDexamethasoneAdjuvants ImmunologicVertigootorhinolaryngologic diseasesmedicineHumansProspective StudiesHyaluronic AcidProspective cohort studyMeniere DiseaseDexamethasoneRound windowbiologymedicine.diagnostic_testbusiness.industryAuditory ThresholdHearing Loss SuddenMiddle Agedbiology.organism_classificationmedicine.diseaseSensory SystemsTreatment Outcomemedicine.anatomical_structureOtorhinolaryngologyMiddle earAudiometry Pure-ToneFemaleSensorineural hearing lossNeurology (clinical)medicine.symptomAudiometrybusinessmedicine.drugOtology & Neurotology
researchProduct

Intravitreal clindamycin and dexamethasone for zone 1 toxoplasmic retinochoroiditis at twenty-four months.

2009

Purpose To report the anatomic and functional outcomes of intravitreal clindamycin and dexamethasone for the treatment of zone 1 toxoplasmic retinochoroiditis (TRC). Patients had 1 or more of the following indications for local therapy: intolerance to oral medication, contraindication to oral medication because of pregnancy, lack of response despite oral antimicrobial treatment, or treatment with concomitant oral and local therapy to avoid or limit foveal or optic disc involvement. Design Noncomparative, retrospective, multicentric interventional case series. Participants We reviewed the medical records of 12 consecutive patients (eyes) with posterior pole (zone 1) TRC who were treated week…

AdultMalemedicine.medical_specialtyVisual acuitygenetic structuresEye diseasePosterior poleAntiprotozoal AgentsVisual AcuityDexamethasoneInjectionsYoung AdultPregnancymedicineHumansFluorescein AngiographyToxoplasmosis OcularContraindicationGlucocorticoidsAntibacterial agentRetrospective Studiesmedicine.diagnostic_testbusiness.industryClindamycinDiabetic retinopathyMiddle Agedmedicine.diseaseFluorescein angiographyeye diseasesSurgeryVitreous BodyOphthalmologyTreatment OutcomeChorioretinitisPregnancy Complications ParasiticDrug Therapy CombinationFemalesense organsmedicine.symptombusinessTomography Optical CoherenceRetinopathyFollow-Up StudiesOphthalmology
researchProduct

[Treatment of sensorineural hearing loss in acute viral otitis media with intratympanic dexamethasone and hyaluronic acid in comparison with intraven…

2006

Background: Intratympanic dexamethasone with hyaluronic acid has shown to be an effective treatment of the inner ear damage in sudden hearing loss and Meniere's disease. It is not known yet if the same applies to the toxic inner ear damage in acute viral otitis media. Patients: Retrospectively, 26 patients who suffered from acute viral otitis media with sensorineural hearing loss were examined with regard to the improvement of their inner ear hearing loss. Twelve patients were treated with intravenous therapy only, consisting of hydroxyethylstarch, pentoxifylline and prednisolone. Fourteen patients additionally received intratympanic injections, consisting of dexamethasone and hyaluronic ac…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentHearing Loss SensorineuralPrednisoloneVasodilator AgentsAnti-Inflammatory AgentsEar MiddleDexamethasonePentoxifyllineInjectionsHydroxyethyl Starch DerivativesAdjuvants ImmunologicAudiometryotorhinolaryngologic diseasesmedicineHumansHyaluronic AcidPentoxifyllineInfusions IntravenousDexamethasoneRetrospective StudiesRound windowmedicine.diagnostic_testbusiness.industryMiddle Agedmedicine.diseaseSurgeryOtitis MediaOtitismedicine.anatomical_structureOtorhinolaryngologyIntravenous therapyAnesthesiaData Interpretation StatisticalAcute DiseasePrednisoloneSensorineural hearing lossDrug Therapy CombinationFemalesense organsmedicine.symptomAudiometrybusinessBone Conductionmedicine.drugLaryngo- rhino- otologie
researchProduct

Blunted cortisol response to stress in patients with eating disorders: Its association to bulimic features

2017

ObjectiveClinical research on cortisol response to stress in patients with eating disorders has provided controversial and even contradictory results. As this might be the consequence of the inclusion in the studies of heterogeneous clinical populations, 3 highly selected samples were studied. MethodsDexamethasone suppression test was performed on 15 restricting anorexia nervosa patients without history of bulimia nervosa (BN), 17 BN patients with normal weight and no history of anorexia nervosa, and 22 healthy controls. Three days later, the Trier Social Stress Test was applied, and 8 saliva samples were collected along the trial for cortisol assessment. ResultsWhen the patients were consi…

AdultSalivaAnorexia NervosaHydrocortisoneTrier Social Stress TestPhysiologyeating disorderscortisol03 medical and health sciencesstress0302 clinical medicinemental disordersmedicineTrier social stress testHumansBulimiaBulimia NervosaSalivaAssociation (psychology)business.industryBulimia nervosahypothalamus-pituitary-adrenal axismedicine.disease030227 psychiatryPsychiatry and Mental healthClinical PsychologyEating disordersClinical researchAnorexia nervosa (differential diagnoses)Dexamethasone suppression testbusinessStress Psychological030217 neurology & neurosurgeryhormones hormone substitutes and hormone antagonists
researchProduct

Ovarian suppression reduces clinical and endocrine expression of late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

1994

Objective To determine the effectiveness of GnRH-agonist (GnRH-a) treatment in women with late onset congenital adrenal hyperplasia. Design Prospective assessment of GnRH-a treatment in six women with documented late-on-set congenital adrenal hyperplasia who were not preselected. Comparisons were made to previous responses in the same patients receiving dexamethasone. Eight age- and weight-matched ovulatory women served as controls. Setting Academic medical center. Intervention Baseline blood determinations before and after IV ACTH, before and after 6months of GnRH-a treatment. Estrogen and progestin replacement was begun in all women after the 3rd month of treatment. Main Outcome Measures …

Adultendocrine systemmedicine.medical_specialtyHirsutismAdolescentmedicine.drug_classOvaryDexamethasoneInternal medicineEndocrine GlandsmedicineHydroxyprogesteronesHumansCongenital adrenal hyperplasiaProspective StudiesAge of OnsethirsutismDexamethasoneTriptorelin PamoatebiologyAdrenal Hyperplasia Congenitalbusiness.industry17-alpha-HydroxyprogesteroneOvary21-HydroxylaseObstetrics and Gynecologymedicine.diseaseAndrogenmedicine.anatomical_structureEndocrinologyReproductive MedicineEstrogenbiology.proteinAndrogensFemalebusinessProgestinhormones hormone substitutes and hormone antagonistsGonadotropinsmedicine.drugFertility and sterility
researchProduct

The ratio of androstenedione: 11β-hydroxyandrostenedione is an important marker of adrenal androgen excess in women

1992

To determine if the ratio of serum androstenedione (A):11 beta-hydroxyandrostenedione (OHA) would be helpful in differentiating adrenal from ovarian hyperandrogenism.Prospective study of outpatients being evaluated for hyperandrogenism.Normal women (n = 27), those with hyperandrogenic chronic anovulation (n = 25), and 7 with adult onset of congenital adrenal hyperplasia (CAH) because of 21-hydroxylase deficiency.Fasting serum between 8:00 A.M. and 9:00 A.M. Patients with hyperandrogenic chronic anovulation and CAH received dexamethasone (DEX) 2 mg for 7 days.Serum testosterone (T), unbound T, dehydroepiandrosterone sulfate (DHEAS), A, and 11 beta-OHA by radioimmunoassay.Serum 11 beta-OHA an…

Adultmedicine.medical_specialtyAdolescentmedicine.drug_classAdrenal Gland DiseasesRadioimmunoassayDexamethasoneAnovulationchemistry.chemical_compoundDehydroepiandrosterone sulfateInternal medicineAdrenal GlandsmedicineHumansCongenital adrenal hyperplasiaProspective StudiesAndrostenedioneDexamethasoneHyperplasiaAdrenal Hyperplasia Congenitalbusiness.industryHyperandrogenismAndrostenedioneObstetrics and GynecologyRadioimmunoassaymedicine.diseaseAndrogenEndocrinologyReproductive MedicinechemistryAndrogensFemalebusinessBiomarkersmedicine.drugFertility and Sterility
researchProduct

Peripheral androgen blockade versus glandular androgen suppression in the treatment of hirsutism.

1991

Hirsutism in women is often explained on the basis of abnormal peripheral androgen metabolism. To determine whether serum markers of ovarian, adrenal, or peripheral androgen production may be helpful determinants in the treatment of hirsutism and to compare the efficacy of treatment with dexamethasone or spironolactone, 20 hyperandrogenic hirsute patients were treated for up to 2 years. Eleven women who were selected on the basis of sensitivity to dexamethasone were treated with a daily dose of 0.37 mg dexamethasone and had androgen levels suppressed into the normal range. Although significant (P less than .05), Ferriman-Gallwey scores decreased only by 20%: 14.2 +/- 0.5 to 11.4 +/- 0.6. Ni…

Adultmedicine.medical_specialtyHirsutismAdolescentmedicine.drug_classmedicine.medical_treatmentSpironolactoneAndrogen suppressionAntiandrogenAndrosteroneDexamethasonechemistry.chemical_compoundInternal medicinemedicineHumansTestosteronehirsutismDexamethasoneChemotherapybusiness.industryDehydroepiandrosterone SulfateAndrostenedioneObstetrics and GynecologyAndrogen AntagonistsDihydrotestosteroneGeneral MedicineDehydroepiandrosteroneAndrogenmedicine.diseaseAndrostane-317-diolDrug CombinationsEndocrinologychemistrySpironolactoneAndrogensCorticosteroidFemalebusinessmedicine.drugObstetrics and gynecology
researchProduct